scholarly article | Q13442814 |
P356 | DOI | 10.1016/S0732-8893(03)00086-5 |
P698 | PubMed publication ID | 12944017 |
P50 | author | Mateu Espasa | Q73874855 |
P2093 | author name string | J A Martínez | |
J Mensa | |||
F Marco | |||
M Almela | |||
M T Jiménez de Anta | |||
J Puig de la Bellacasa | |||
A Jurado | |||
C Danés | |||
P2860 | cites work | In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi | Q28343817 |
Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans | Q28379123 | ||
In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp | Q28379320 | ||
International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobia | Q30453797 | ||
Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. | Q33980029 | ||
Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. | Q34085884 | ||
In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents. | Q35134781 | ||
Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients | Q35819117 | ||
Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review | Q35997161 | ||
The new fungal opportunists are coming | Q41044994 | ||
The epidemiology of candidemia in two United States cities: results of a population-based active surveillance | Q41696774 | ||
Increase inCandida kruseiInfection among Patients with Bone Marrow Transplantation and Neutropenia Treated Prophylactically with Fluconazole | Q43543160 | ||
Candida parapsilosis Fungemia Associated with Implantable and Semi-Implantable Central Venous Catheters and the Hands of Healthcare Workers | Q63197408 | ||
The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance | Q71181685 | ||
Evolving risk factors for invasive fungal infections--all neutropenic patients are not the same | Q72160665 | ||
International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group | Q73102772 | ||
The epidemiology of hematogenous candidiasis caused by different Candida species | Q73441200 | ||
Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp | Q77474976 | ||
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | voriconazole | Q412236 |
P304 | page(s) | 259-264 | |
P577 | publication date | 2003-08-01 | |
P1433 | published in | Diagnostic Microbiology and Infectious Disease | Q15763479 |
P1476 | title | Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. Results from a six-year study (1996-2001) | |
P478 | volume | 46 |
Q46885843 | (B1) Candida and mycotic infections |
Q38175195 | A single center's experience with Candida parapsilosis related long-term central venous access device infections: the port removal decision and its outcomes |
Q45084559 | Anidulafungin |
Q34036214 | Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome |
Q42846025 | Antifungal drug susceptibility profile of Pichia anomala isolates from patients presenting with nosocomial fungemia. |
Q41909634 | Are Anidulafungin or Voriconazole Released from Polymethylmethacrylate In Vitro? |
Q34719843 | Candida guilliermondii fungemia in patients with hematologic malignancies |
Q34852747 | Candida parapsilosis, an emerging fungal pathogen |
Q37613000 | Candida parapsilosis: a review of its epidemiology, pathogenesis, clinical aspects, typing and antimicrobial susceptibility |
Q91983100 | Candida parapsilosis: from Genes to the Bedside |
Q55379370 | D-Cateslytin: a new antifungal agent for the treatment of oral Candida albicans associated infections. |
Q36441524 | Echinocandin antifungals: review and update |
Q36458402 | Emerging echinocandins for treatment of invasive fungal infections |
Q40458611 | Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain. |
Q36308069 | Epidemiology and echinocandin susceptibility of Candida parapsilosis sensu lato species isolated from bloodstream infections at a Spanish university hospital. |
Q40757551 | Epidemiology of candidaemia in a tertiary care university hospital: 10-year experience with 381 candidaemia episodes between 2001 and 2010. |
Q43250363 | High incidence of Candida parapsilosis candidaemia in non-neutropenic critically ill patients: epidemiology and antifungal susceptibility. |
Q37608276 | New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance |
Q36491819 | Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations |
Q33910250 | One year prospective survey of Candida bloodstream infections in Scotland. |
Q34303424 | Oropharyngeal Candida colonization in human immunodeficiency virus infected patients |
Q42284150 | Pharmacokinetics of fosfluconazole and fluconazole following multiple intravenous administration of fosfluconazole in healthy male volunteers |
Q35587733 | The diagnosis of hepatosplenic candidiasis by DNA analysis of tissue biopsy and serum |
Q35166823 | Voriconazole in the management of nosocomial invasive fungal infections |